Seneca Biopharma (STU:7NS2) Debt-to-Asset : 0.00 (As of Dec. 2020)

View and export this data going back to 2013. Start your Free Trial

What is Seneca Biopharma Debt-to-Asset?

Seneca Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was €0.00 Mil. Seneca Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was €0.00 Mil. Seneca Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2020 was €10.73 Mil. Seneca Biopharma's debt to asset for the quarter that ended in Dec. 2020 was 0.00.

Seneca Biopharma Debt-to-Asset Historical Data

The historical data trend for Seneca Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seneca Biopharma Debt-to-Asset Chart

Seneca Biopharma Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Asset

Get a 7-Day Free Trial

0.16

0.03

0.06

Seneca Biopharma Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Debt-to-Asset	Get a 7-Day Free Trial															0.06	0.02	0.01	-	-

Competitive Comparison of Seneca Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Seneca Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seneca Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seneca Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Seneca Biopharma's Debt-to-Asset falls into.

Seneca Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Seneca Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	10.726
	=	0.00

Seneca Biopharma's Debt-to-Asset for the quarter that ended in Dec. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	10.726
	=	0.00

Seneca Biopharma (STU:7NS2) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Seneca Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Seneca Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Seneca Biopharma (STU:7NS2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seneca Biopharma Inc (STU:7NS2) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

20271 Goldenrod Lane, Suite 2024, Germantown, MD, USA, 20876

Website

https://www.senecabio.com

Seneca Biopharma Inc is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. It is focused on the research and development of nervous system therapies based on proprietary human neural stem cells and small molecule compounds.

Seneca Biopharma (STU:7NS2) Headlines

No Headlines